Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

J&J Expects Paliperidone To Receive FDA “Approvable” Letter

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

However, the company plans to move very quickly toward approval.

You may also be interested in...



J&J's Invega Will Launch In January As Follow-On To Risperdal

Paliperidone is the first atypical antipsychotic to be approved since 2003.

J&J's Invega Will Launch In January As Follow-On To Risperdal

Paliperidone is the first atypical antipsychotic to be approved since 2003.

Paliperidone “Approvable” Puts Pressure On J&J Evergreening Strategy

While not unexpected, the regulatory delay means the company will have less time to transition patients to the Risperdal follow-on.

Table

View full table

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By